Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP)

Background: Brigatinib has demonstrated its efficacy as first-line therapy and in further lines for ALK-positive non-small cell lung cancer (NSCLC) patients; however, real-world data in Latin America are scarce. Methods: From January 2018 to March 2020, 46 patients with advanced ALK-positive NSCLC received brigatinib as second or further line of therapy in Mexico and Colombia. The primary end point was progression-free survival (PFS); secondary end point was time to treatment discontinuation (TTD). Results: At a median follow-up of 9.3 months, the median PFS was 15.2 months (95% CI: 11.6-18.8), and TTD was 18.46 months (95% CI: 9.54-27.38). The estimated overall survival at 12 months was 80%. Safety profile was consistent with previously published data. Conclusion: Brigatinib is an effective treatment for previously treated ALK-positive NSCLC patients in a real-world setting.

• Autores: Heredia, David; Barrón-Barrón, Feliciano; Cardona, Andrés Felipe; Campos, Saul T.; Rodríguez-Cid, Jerónimo Rafael; Martínez-Barrera, Luis Manuel; Alatorre, Jorge; Salinas, Miguel Ángel; Lara-Mejía, Luis; Flores-Estrada, Diana; Arrieta, Oscar
• Tipo de recurso: Article of journal
• Fecha de publicación: 2021
• Institución: Universidad El Bosque
• Repositorio: Repositorio U. El Bosque
• Idioma: eng
• OAI Identifier: oai:repositorio.unbosque.edu.co:20.500.12495/5776
• Acceso en línea: http://hdl.handle.net/20.500.12495/5776; https://doi.org/10.2217/fon-2020-0747
• Palabra clave: Anaplastic lymphoma kinase; Brigatinib; Ceritinib; Crizotinib; Early access; Lung cancer; Non-small cell lung cancer; Real-world evidence
• Rights: openAccess
• License: Acceso abierto